Ovarian angiosarcoma: Extended survival following optimal cytoreductive surgery and adjuvant chemotherapy.
作者信息
Guseh Stephanie H, Bradford Leslie S, Hariri Lida P, Schorge John O
机构信息
Department of Obstetrics and Gynecology, Massachusetts General Hospital, USA ; Department of Obstetrics, Gynecology and Reproductive Biology, Brigham & Women's Hospital, USA.
Division of Gynecologic Oncology, Massachusetts General Hospital, USA.
出版信息
Gynecol Oncol Case Rep. 2012 Dec 20;4:23-5. doi: 10.1016/j.gynor.2012.12.006. eCollection 2012.
Abstract
摘要
相似文献
1
Ovarian angiosarcoma: Extended survival following optimal cytoreductive surgery and adjuvant chemotherapy.卵巢血管肉瘤：最佳肿瘤细胞减灭术及辅助化疗后的生存期延长
Gynecol Oncol Case Rep. 2012 Dec 20;4:23-5. doi: 10.1016/j.gynor.2012.12.006. eCollection 2012.
2
[Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].新辅助化疗对Ⅲc期和Ⅳ期上皮性卵巢癌患者生存的影响
Zhonghua Zhong Liu Za Zhi. 2008 Apr;30(4):298-301.
3
The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer.新辅助化疗和细胞减灭术对晚期卵巢癌 10 年生存率的影响。
Int J Gynaecol Obstet. 2021 Jun;153(3):417-423. doi: 10.1002/ijgo.13542. Epub 2021 Jan 13.
4
5
Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy.儿童卵巢血管肉瘤采用全身化疗和细胞减灭术联合腹腔内热化疗治疗：病例报告及治疗回顾。
Pediatr Blood Cancer. 2019 Jul;66(7):e27753. doi: 10.1002/pbc.27753. Epub 2019 Apr 11.
6
Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer.原发性细胞减灭术后至辅助化疗开始时间对晚期上皮性卵巢癌的影响。
Int J Gynaecol Obstet. 2018 Dec;143(3):325-332. doi: 10.1002/ijgo.12653. Epub 2018 Sep 19.
7
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.减瘤手术联合化疗与单纯化疗治疗复发性铂敏感上皮性卵巢癌（SOCceR试验）：一项多中心随机对照研究
BMC Cancer. 2014 Jan 14;14:22. doi: 10.1186/1471-2407-14-22.
8
Optimal primary therapy of ovarian cancer.卵巢癌的最佳初始治疗。
Ann Oncol. 2016 Apr;27 Suppl 1:i58-i62. doi: 10.1093/annonc/mdw088.
9
Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.年龄校正的Charlson共病指数对晚期上皮性卵巢癌新辅助化疗后行肿瘤细胞减灭术患者围手术期并发症、辅助化疗使用情况及生存的预测价值。
J Obstet Gynaecol. 2017 Nov;37(8):1070-1075. doi: 10.1080/01443615.2017.1324413. Epub 2017 Jul 25.
10
Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.原发性细胞减灭术联合或不联合腹腔热灌注化疗（HIPEC）治疗国际妇产科联盟（FIGO）分期 III 期上皮性卵巢癌：OVHIPEC-2，一项 III 期随机临床试验。
Int J Gynecol Cancer. 2020 Jun;30(6):888-892. doi: 10.1136/ijgc-2020-001231. Epub 2020 Mar 23.
引用本文的文献
1
Ovarian Angiosarcoma With Intractable Intraperitoneal Hemorrhage: A Case Report and Review of the Literature.伴有顽固性腹腔内出血的卵巢血管肉瘤：一例报告并文献复习
Cureus. 2025 Jan 3;17(1):e76849. doi: 10.7759/cureus.76849. eCollection 2025 Jan.
2
Angiosarcoma of the ovary treated with polyadenosine ribose polymerase Inhibition, a case report and review of the literature.聚腺苷酸核糖聚合酶抑制治疗卵巢血管肉瘤：一例报告并文献复习
Gynecol Oncol Rep. 2023 Aug 23;49:101264. doi: 10.1016/j.gore.2023.101264. eCollection 2023 Oct.
3
Clinical analysis of 12 cases of ovarian cystic mature teratoma with malignant transformation into squamous cell carcinoma.12例卵巢囊性成熟畸胎瘤恶变成为鳞状细胞癌的临床分析
J Int Med Res. 2021 Feb;49(2):300060520981549. doi: 10.1177/0300060520981549.
4
Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor.原发性卵巢血管肉瘤：一种罕见且可识别的卵巢肿瘤。
J Ovarian Res. 2021 Jan 28;14(1):21. doi: 10.1186/s13048-021-00771-7.
5
Bilateral ovarian angiosarcoma arising from the mature cystic teratomas - A case report and review of the literature.起源于成熟囊性畸胎瘤的双侧卵巢血管肉瘤——病例报告及文献复习
Int J Surg Case Rep. 2018;42:90-93. doi: 10.1016/j.ijscr.2017.11.064. Epub 2017 Dec 7.
6
Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification.基于吉西他滨的方案治疗伴有MYC扩增的原发性卵巢血管肉瘤
Curr Oncol. 2014 Dec;21(6):e782-9. doi: 10.3747/co.21.2144.
本文引用的文献
1
Primary angiosarcoma of the ovary with prominent fibrosis of the ovarian stroma. Case report of an 81-year old patient.卵巢原发性血管肉瘤伴卵巢间质显著纤维化。1 例 81 岁患者报告。
Diagn Pathol. 2011 Jul 14;6:65. doi: 10.1186/1746-1596-6-65.
2
Angiosarcoma: state of the art and perspectives.血管肉瘤：现状与展望。
Crit Rev Oncol Hematol. 2011 Nov;80(2):257-63. doi: 10.1016/j.critrevonc.2010.10.007. Epub 2010 Nov 4.
3
Histology-driven chemotherapy of soft-tissue sarcoma.组织学驱动的软组织肉瘤化疗。
Ann Oncol. 2010 Oct;21 Suppl 7:vii270-6. doi: 10.1093/annonc/mdq285.
4
Angiosarcoma.血管肉瘤。
Lancet Oncol. 2010 Oct;11(10):983-91. doi: 10.1016/S1470-2045(10)70023-1. Epub 2010 May 25.
5
Primary angiosarcoma of the ovary complicated by hemoperitoneum: a case report and review of the literature.卵巢原发性血管肉瘤并发血腹：病例报告及文献复习。
Arch Gynecol Obstet. 2010 Jan;281(1):145-50. doi: 10.1007/s00404-009-1092-2. Epub 2009 Apr 25.
6
Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.每周一次紫杉醇治疗不可切除血管肉瘤的II期试验：ANGIOTAX研究
J Clin Oncol. 2008 Nov 10;26(32):5269-74. doi: 10.1200/JCO.2008.17.3146. Epub 2008 Sep 22.
7
Angiosarcomas and taxanes.血管肉瘤与紫杉烷类药物。
Curr Treat Options Oncol. 2007 Dec;8(6):428-34. doi: 10.1007/s11864-007-0042-0. Epub 2007 Dec 8.
8
Primary angiosarcoma of the ovary: a case report of Stage I disease.卵巢原发性血管肉瘤：1期疾病的病例报告
Gynecol Oncol. 2005 Oct;99(1):218-21. doi: 10.1016/j.ygyno.2005.05.044.
Zotero 插件